Glucagon Clinical Intervention Protocols (2026)

Practice vocabulary and clinical administration details for Glucagon and Baqsimi based on the 2026 primary care paramedic protocols.

Glucagon (Therapeutic Class)

Hormone hyperglycémiante (hyperglycemic hormone).

Hypoglycemia Threshold for Glucagon

A glycemia level lower than $4\,mmol/L$ with an inability to take PO glucose solution or $15$ minutes after a 2nd dose of PO glucose solution.

GlucaGenMD Contraindication

Anaphylaxis to latex.

Baqsimi Presentation

Nasal injector containing $3\,mg$ of glucagon powder.

Baqsimi Dosage ($\ge 4$ years)

$3\,mg$ IN via Baqsimi nasal injector.

Glucagon IM Dosage (< 25\,kg)

$0,5\,mg$ ($0,5\,ml$) administered intramuscularly.

Glucagon IM Dosage ($\ge 25\,kg$)

$1\,mg$ ($1\,ml$ or the total content of the vial) administered intramuscularly.

Glucagon Repetition Protocol

One repetition allowed $15$ minutes after the first dose if indications are still present.

Glucagon Adverse Effects

Nausea and vomiting.

Baqsimi Administration Confirmation

The dose is administered when the plunger (piston) crosses the second level of pressure.

Glucagon Onset of Action

$5$ to $15$ minutes.

Glucagon Bioavailability (IM)

$80$ to $90\,\%$.

Glucagon Half-life (IM)

$30$ to $45$ minutes.

Glucagon Maximum Duration of Effect

$60$ to $90$ minutes.

Glucagon Metabolism

Hepatic, plasma, and renal.